Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.
Prostate Cancer Awareness Month: The Evolving Role of Radioligand Therapy
Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the evolving role of radioligand therapies for the treatment of PSMA-positive prostate cancer.
Scott T. Tagawa, MD, MS, FACP, FASCO, details factors to consider when to use or defer docetaxel after lutetium Lu 177 vipivotide tetraxetan in mCRPC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5